Table 3.
First-Line Chemotherapy
| Group | Total (n = 49) | Nivolumab (n = 17) | Conventional Treatment (n = 32a) | p Value |
|---|---|---|---|---|
| Type of chemotherapy, n (%) | 0.0406 | |||
| Plt-Eto | 42 (86) | 12 (71) | 30 (94) | |
| Other | 7 (14) | 5 (29) | 2 (6) | |
| Reason for stopping treatment, n (%) | 0.1551 | |||
| Treatment completed | 8 (16) | 1 (6) | 7 (21) | |
| Disease progression | 21 (41) | 10 (59) | 11 (32) | |
| Toxicity | 6 (12) | 2 (12) | 4 (12) | |
| Medical decision | 10 (20) | 3 (18) | 7 (21) | |
| Patient’s preference | 1 (2) | 1 (6) | 0 (0) | |
| Death | 5 (10) | 0 (0) | 5 (15) | |
| Efficacy | ||||
| ORR (%) [95% CI] | (29.4) [17.5–43.8] | (23.5) [6.8-–49.9] | (32.4) [17.4–50.5] | 0.5145 |
| PFS (mo), median [95% CI] | — | 3.5 [1.7–4.4] | 2.1 [1.4–4.2] | 0.5427 |
CI, confidence interval; Eto, etoposide; ORR, objective response rate; PFS, progression-free survival; Plt, platinum.
a
Missing data.